1. Home
  2. PMTS vs TNXP Comparison

PMTS vs TNXP Comparison

Compare PMTS & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CPI Card Group Inc.

PMTS

CPI Card Group Inc.

HOLD

Current Price

$14.12

Market Cap

183.1M

Sector

Finance

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$19.34

Market Cap

197.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMTS
TNXP
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.1M
197.9M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PMTS
TNXP
Price
$14.12
$19.34
Analyst Decision
Strong Buy
Buy
Analyst Count
4
1
Target Price
$32.00
$70.00
AVG Volume (30 Days)
50.0K
807.7K
Earning Date
11-04-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.20
N/A
Revenue
$515,576,000.00
$10,299,000.00
Revenue This Year
$14.84
$14.79
Revenue Next Year
$10.55
$933.49
P/E Ratio
$11.82
N/A
Revenue Growth
12.48
N/A
52 Week Low
$11.64
$6.76
52 Week High
$35.19
$130.00

Technical Indicators

Market Signals
Indicator
PMTS
TNXP
Relative Strength Index (RSI) 54.04 58.73
Support Level $13.03 $15.10
Resistance Level $14.36 $16.18
Average True Range (ATR) 0.64 1.39
MACD 0.26 0.61
Stochastic Oscillator 96.70 92.10

Price Performance

Historical Comparison
PMTS
TNXP

About PMTS CPI Card Group Inc.

CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: